[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644477":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":25,"locations":31,"responsibleParty":45,"collaborators":11,"id":47,"slug":11,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":11,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":11,"enrollmentInfo":55,"targetDuration":11,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":68,"overallStatus":80,"whyStopped":11,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"RayzeBio, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"RYZ211\u002F212","EXPERIMENTAL",null,[13],"Diagnostic Test: RYZ211\u002F212",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DIAGNOSTIC_TEST","Imaging Agent",[9],[20,23],{"name":21,"affiliation":5,"role":22},"Freddy Escorcia","STUDY_DIRECTOR",{"name":24,"affiliation":5,"role":22},"Heying Duan",[26],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},"RayzeBio Clinical Trials","CONTACT","(619) 657-0057","clinicaltrials@rayzebio.com",[32],{"facility":33,"status":11,"city":34,"state":11,"zip":11,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Research Facility","Christchurch","New Zealand",{"type":37,"coordinates":38},"Point",[39,40],172.63333,-43.53333,{"lat":40,"lon":39},[43],{"name":44,"role":28,"phone":11,"phoneExt":11,"email":11},"Site Contact",{"type":46,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100644477",false,"NCT07671092","Imaging Study of a TROP2 Binder in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC","A Phase 0 Imaging Study to Assess the Feasibility, Biodistribution, and Dosimetry of a Trophoblast Cell Surface Antigen 2 (TROP2) Binder in Metastatic Urothelial Cancer (UC), Hormone Receptor-Positive (HR+) and Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Breast Cancer, Triple-Negative Breast Cancer (TNBC), and Non-Small-Cell Lung Cancer (NSCLC)","Inclusion Criteria:\n\n* Are at least 18 years old at the time of signing the informed consent form (ICF)\n* Have biopsy proven metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC\n\nExclusion Criteria:\n\n* TROP2-targeting antibody-drug conjugates (ADCs) such as sacituzumab govitecan or datopotamab deruxtecan, should be discontinued at least 90 days prior to administration of RYZ211 and RYZ212\n* For Women of Childbearing Potential: Are pregnant or breastfeeding\n\nNote: Additional criteria may apply and will be assessed by the study site","ALL","18 Years",{"count":56,"type":57},40,"ESTIMATED","INTERVENTIONAL",[60],"EARLY_PHASE1","This imaging study aims to assess the feasibility, biodistribution, and dosimetry of a TROP2 binder in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.",[63,64,65,66,67],"Metastatic Urothelial Carcinoma","Breast Cancer","TNBC - Triple-Negative Breast Cancer","Hormone Receptor Positive HER-2 Negative Breast Cancer","NSCLC",[69,70,64,71,72,73,74,75,76,77,78,79,17],"HR+","HER2-","Non Small Cell Lung Cancer","Triple Negative Breast Cancer","Trop2","TNBC","RayzeBio","Rayze","BMS","Bristol Myers Squibb","RPT","NOT_YET_RECRUITING","2026-06-22",{"date":83,"type":84},"2026-06-26","ACTUAL",{"date":86,"type":57},"2026-06",{"date":88,"type":57},"2027-10",{"name":5,"class":6},1]